Qamsari Elmira Safaie, Sharifzadeh Zahra, Bagheri Salman, Riazi-Rad Farhad, Younesi Vahid, Abolhassani Mohsen, Ghaderi Sepideh Safaei, Baradaran Behzad, Somi Mohammad Hossein, Yousefi Mehdi
a Immunology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.
b Department of Immunology , Tabriz University of Medical Sciences , Tabriz , Iran.
J Immunotoxicol. 2017 Dec;14(1):23-30. doi: 10.1080/1547691X.2016.1251512. Epub 2017 Jan 16.
The receptor tyrosine kinase (RTK) Met is the cell surface receptor for hepatocyte growth factor (HGF) involved in invasive growth programs during embryogenesis and tumorgenesis. There is compelling evidence suggesting important roles for c-Met in colorectal cancer proliferation, migration, invasion, angiogenesis, and survival. Hence, a molecular inhibitor of an extracellular domain of c-Met receptor that blocks c-Met-cell surface interactions could be of great thera-peutic importance. In an attempt to develop molecular inhibitors of c-Met, single chain variable fragment (scFv) phage display libraries Tomlinson I + J against a specific synthetic oligopeptide from the extracellular domain of c-Met receptor were screened; selected scFv were then characterized using various immune techniques. Three c-Met specific scFv (ES1, ES2, and ES3) were selected following five rounds of panning procedures. The scFv showed specific binding to c-Met receptor, and significantly inhibited proliferation responses of a human colorectal carcinoma cell line (HCT-116). Moreover, anti- apoptotic effects of selected scFv antibodies on the HCT-116 cell line were also evaluated using Annexin V/PI assays. The results demonstrated rates of apoptotic cell death of 46.0, 25.5, and 37.8% among these cells were induced by use of ES1, ES2, and ES3, respectively. The results demonstrated ability to successfully isolate/char-acterize specific c-Met scFv that could ultimately have a great therapeutic potential in immuno-therapies against (colorectal) cancers.
受体酪氨酸激酶(RTK)Met是肝细胞生长因子(HGF)的细胞表面受体,参与胚胎发生和肿瘤发生过程中的侵袭性生长程序。有令人信服的证据表明c-Met在结直肠癌的增殖、迁移、侵袭、血管生成和存活中发挥重要作用。因此,一种能够阻断c-Met与细胞表面相互作用的c-Met受体细胞外结构域分子抑制剂可能具有重要的治疗意义。为了开发c-Met的分子抑制剂,我们筛选了针对c-Met受体细胞外结构域特定合成寡肽的单链可变片段(scFv)噬菌体展示文库Tomlinson I + J;然后使用各种免疫技术对筛选出的scFv进行表征。经过五轮淘选程序,筛选出了三种c-Met特异性scFv(ES1、ES2和ES3)。这些scFv显示出与c-Met受体的特异性结合,并显著抑制了人结肠癌细胞系(HCT-116)的增殖反应。此外,还使用Annexin V/PI分析评估了所选scFv抗体对HCT-116细胞系的抗凋亡作用。结果表明,使用ES1、ES2和ES3分别诱导这些细胞的凋亡细胞死亡率为46.0%、25.5%和37.8%。结果证明能够成功分离/表征特异性c-Met scFv,其最终在针对(结)直肠癌的免疫治疗中可能具有巨大的治疗潜力。